11:05 AM EDT, 06/04/2024 (MT Newswires) -- Gilead Sciences ( GILD ) said Tuesday it has agreed to make a one-time payment of up to $40 million to about 2,625 plaintiffs to resolve claims related to the pending federal tenofovir disoproxil fumarate, or TDF, litigation in the US District Court for the Northern District of California.

TDF is a prescription medicine for the treatment of HIV, or human immunodeficiency virus, infection.

The settlement is contingent upon specific conditions, including at least 98% of these eligible plaintiffs opting for the agreement, the drugmaker said.

Gilead said it entered into an agreement to avoid the expense and distraction of litigation but the settlement is not an admission of any liability or wrongdoing.

This agreement excludes the California state TDF lawsuit currently pending in the California Supreme Court, the company added.

Price: 64.22, Change: +0.79, Percent Change: +1.25